VC
NERV icon

Vivo Capital’s Minerva Neurosciences NERV Stock Holding History

Vivo Capital’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26M Hold
4,322,747
– – 2.17% 15
2025
Q4 		$17.4M Buy
+4,322,747
New +$16.1M 1.12% 24
2016
Q3 		– Sell
-25,000
Closed -$2.04M – 24
2016
Q2 		$2.04M Buy
+25,000
New +$1.59M 0.56% 17

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vivo Capital's NERV Position: Q1 2026 in Review

Vivo Capital held its Minerva Neurosciences (NERV) position steady in Q1 2026 at 4,322,747 shares worth $26M. The position accounts for 2.17% of the portfolio, ranked #15.

Vivo Capital first reported a position in NERV in Q2 2016 and has held it in 3 quarters since. 47 funds tracked by Wall St. Rank hold NERV as of Q1 2026.

  • Vivo Capital held 4,322,747 shares of Minerva Neurosciences worth $26M as of Q1 2026.
  • Vivo Capital left its Minerva Neurosciences share count unchanged in Q1 2026.
  • Minerva Neurosciences made up 2.17% of Vivo Capital's portfolio in Q1 2026, its #15 holding.
  • Vivo Capital first reported a position in Minerva Neurosciences in Q2 2016 and has held it in 3 quarters since.
  • 47 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2026.

Based on Vivo Capital's 13F filing for Q1 2026, filed 15 May 2026.